Lorena Lorefice
Overview
Explore the profile of Lorena Lorefice including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nociti V, Romozzi M, Annovazzi P, Fantozzi R, Tortorella C, Vercellino M, et al.
J Neurol Sci
. 2025 Jan;
469():123392.
PMID: 39808882
Background: Migraine affects up to 40% of people with multiple sclerosis (PwMS). This study aimed to evaluate the effectiveness and safety of the combination of antibodies (mAbs) against CGRP (anti-CGRP...
2.
Nociti V, Romozzi M, Prosperini L, Torri Clerici V, Ragonese P, Gallo A, et al.
Eur J Neurol
. 2024 Dec;
32(1):e70019.
PMID: 39722573
Background: The study aims to examine the age and disability levels at diagnosis in people with multiple sclerosis (PwMS), with and without autoimmune comorbidities (AC), and the effect of AC...
3.
Zoledziewska M, Lorefice L
Neurodegener Dis Manag
. 2024 Nov;
14(6):189-192.
PMID: 39600266
No abstract available.
4.
Lorefice L, Zoledziewska M
Nutrients
. 2024 Nov;
16(22).
PMID: 39599673
Accumulating evidence suggests that multiple sclerosis (MS) is an environmentally influenced disorder with contributions from life-time exposure to factors including Epstein-Barr virus infection or shifts in microbiome, diet and lifestyle....
5.
Landi D, Bartolomeo S, Bovis F, Amato M, Bonavita S, Borriello G, et al.
Mult Scler
. 2024 Sep;
30(11-12):1503-1513.
PMID: 39263885
Background: Evidence on the impact of dimethyl fumarate (DMF) during pregnancy in women with multiple sclerosis (MS) is limited. Objectives: To investigate disease activity and pregnancy outcomes in a retrospective...
6.
Orru V, Serra V, Marongiu M, Lai S, Lodde V, Zoledziewska M, et al.
Front Immunol
. 2024 Jul;
15:1416464.
PMID: 39076966
Introduction: Disease-modifying therapies (DMTs) have been shown to improve disease outcomes in multiple sclerosis (MS) patients. They may also impair the immune response to vaccines, including the SARS-CoV-2 vaccine. However,...
7.
Lorefice L, Pitzalis M, Zoledziewska M
Mult Scler Relat Disord
. 2024 Jun;
88:105744.
PMID: 38914047
Multiple sclerosis (MS) is a complex neurological disease characterized by great variability in clinical presentation, including the radiological features, and degree of disability. Both genetics and environment contribute to disease...
8.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Lorefice L, Schoonheim M, et al.
Neuroimage Clin
. 2024 May;
42:103609.
PMID: 38718640
Background: Prior research has established a link between thalamic pathology and cognitive impairment (CI) in people with multiple sclerosis (pwMS). However, the translation of these findings to pwMS in everyday...
9.
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, et al.
Eur J Neurol
. 2024 Mar;
31(6):e16250.
PMID: 38549186
Background And Purpose: Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment...
10.
Lorefice L, Mellino P, Frau J, Coghe G, Fenu G, Cocco E
Neurol Sci
. 2024 Mar;
45(8):3951-3959.
PMID: 38472551
Introduction: CD20-depleting therapies are a real milestone in the treatment of multiple sclerosis (MS). This study examined the ocrelizumab (OCR) use in patients with primary progressive (PP) and relapsing remitting...